<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04809818</url>
  </required_header>
  <id_info>
    <org_study_id>LT3001-105</org_study_id>
    <nct_id>NCT04809818</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects</brief_title>
  <official_title>Double-Blind, Randomized, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of LT3001 Drug Product and Drug-Drug Interaction in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lumosa Therapeutics Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lumosa Therapeutics Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 study is planned to establish the clinical safety and pharmacokinetics profile&#xD;
      of multiple dose of LT3001 drug product and to investigate drug interactions of LT3001 with&#xD;
      potential concomitant medications in healthy subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a two-part study. Part A is double-blind, placebo-controlled, and will examine&#xD;
      the safety and PK profiles of multiple doses of LT3001 drug product in healthy subjects. Part&#xD;
      B is open-label and will assess the safety and PK of LT3001 when coadministered with aspirin,&#xD;
      clopidogrel, apixaban or dabigatran.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 21, 2021</start_date>
  <completion_date type="Anticipated">October 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Part A: parallel Part B: single group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>16 days</time_frame>
    <description>To evaluate the safety and tolerability of LT3001 administered alone or with Aspirin, Clopidogrel, Apixaban, Dabigatran determined by number and severity of adverse events from the time of dosing up to 16 days post-dose.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in coagulation</measure>
    <time_frame>16 days</time_frame>
    <description>To evaluate the safety of LT3001 administered alone or with Aspirin, Clopidogrel, Apixaban, Dabigatran determined by coagulation test from baseline up to 16 days post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from baseline in platelet function test</measure>
    <time_frame>16 days</time_frame>
    <description>To evaluate the safety of LT3001 administered alone or with Aspirin, Clopidogrel, Apixaban, Dabigatran determined by platelet function from baseline up to 16 days post-dose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of LT3001 - Cmax</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of LT3001 - Tmax</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of LT3001 - AUC</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma concentrations of LT3001 and derived PK parameters up to 10 days after a single dose or multiple doses intravenous infusion of LT3001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Aspirin - Cmax</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Aspirin - Tmax</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Aspirin - AUC</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma concentrations of Aspirin and derived PK parameters up to 8 days after multiple doses of Aspirin administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Clopidogrel - Cmax</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Clopidogrel - Tmax</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Clopidogrel - AUC</measure>
    <time_frame>10 days</time_frame>
    <description>Plasma concentrations of Clopidogrel and derived PK parameters up to 10 days after multiple doses of Clopidogrel administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Apixaban - Cmax</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Apixaban - Tmax</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Apixaban - AUC</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma concentrations of Apixaban and derived PK parameters up to 8 days after multiple doses of Apixaban administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Dabigatran - Cmax</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Dabigatran - Tmax</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma PK parameters of Dabigatran - AUC</measure>
    <time_frame>8 days</time_frame>
    <description>Plasma concentrations of Dabigatran and derived PK parameters up to 8 days after multiple doses of Dabigatran administered (alone or with LT3001).</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Acute Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Part A - LT3001 Drug Product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LT3001 administered by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A - Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Multiple doses of Placebo administered by intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - LT3001 and Aspirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LT3001 and Aspirin administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - LT3001 and Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LT3001 and Clopidogrel administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - LT3001 and Apixaban</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LT3001 and Apixaban administered</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B - LT3001 and Dabigatran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple doses of LT3001 and Dabigatran administered</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LT3001 drug product</intervention_name>
    <description>Multiple doses of LT3001 drug product administered by intravenous infusion</description>
    <arm_group_label>Part A - LT3001 Drug Product</arm_group_label>
    <arm_group_label>Part B - LT3001 and Apixaban</arm_group_label>
    <arm_group_label>Part B - LT3001 and Aspirin</arm_group_label>
    <arm_group_label>Part B - LT3001 and Clopidogrel</arm_group_label>
    <arm_group_label>Part B - LT3001 and Dabigatran</arm_group_label>
    <other_name>LT3001 injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Multiple doses of Placebo administered by intravenous infusion</description>
    <arm_group_label>Part A - Placebo</arm_group_label>
    <other_name>Placebo of LT3001 drug product</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Loading and maintenance doses of Aspirin administered by oral</description>
    <arm_group_label>Part B - LT3001 and Aspirin</arm_group_label>
    <other_name>Aspirin tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>Loading and maintenance doses of Clopidogrel administered by oral</description>
    <arm_group_label>Part B - LT3001 and Clopidogrel</arm_group_label>
    <other_name>Clopidogrel tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apixaban</intervention_name>
    <description>Multiple doses of Apixaban administered by oral</description>
    <arm_group_label>Part B - LT3001 and Apixaban</arm_group_label>
    <other_name>Eliquis®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dabigatran</intervention_name>
    <description>Multiple doses of Dabigatran administered by oral</description>
    <arm_group_label>Part B - LT3001 and Dabigatran</arm_group_label>
    <other_name>Pradaxa®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject's body weight is ≥50 kg and BMI is within the range of 18 to 32&#xD;
&#xD;
          -  Subject is a healthy volunteer.&#xD;
&#xD;
          -  Subject's PT, aPTT, and TT are within the normal laboratory range.&#xD;
&#xD;
          -  Subject is a nonsmoker&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a current or recent history of regular alcohol consumption.&#xD;
&#xD;
          -  Subjects who are enrolled in Part B and allergic to acetylsalicylic acid, other&#xD;
             salicylates, clopidogrel, thienopyridines (eg, ticlopidine, prasugrel), apixaban or&#xD;
             dabigatran.&#xD;
&#xD;
          -  Part B Cohort 2 only: subjects who are poor metabolizers of clopidogrel (CYP2C19*2/*2,&#xD;
             *2/*3, or *3/*3 genotype)&#xD;
&#xD;
          -  Subject has a presence or history of coagulation abnormality.&#xD;
&#xD;
          -  Subjects need to receive a surgery or clinical procedures associated with high&#xD;
             bleeding risk.&#xD;
&#xD;
          -  Subject has a history of minor bleeding episodes, eg, epistaxis, rectal bleeding,&#xD;
             gingival bleeding.&#xD;
&#xD;
          -  Subject has a history of peptic ulcer or gastrointestinal bleeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mimi Yeh, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Lumosa Phase 1 unit</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kevin Hsiao</last_name>
    <phone>+886226557918</phone>
    <phone_ext>5707</phone_ext>
    <email>kevin_hsiao@lumosa.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lumosa Phase 1 Unit</name>
      <address>
        <city>Cypress</city>
        <state>California</state>
        <zip>90630</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 5, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

